This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Published Erratum

. 2022 May;10(5):e004699corr1.

doi: 10.1136/jitc-2022-004699corr1.

Correction: Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept

No authors listed

PMID: 35640932
PMCID: PMC9157334
DOI: 10.1136/jitc-2022-004699corr1

Published Erratum

Correction: Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept

No authors listed. J Immunother Cancer. 2022 May.

. 2022 May;10(5):e004699corr1.

doi: 10.1136/jitc-2022-004699corr1.

PMID: 35640932
PMCID: PMC9157334
DOI: 10.1136/jitc-2022-004699corr1

No abstract available

PubMed Disclaimer

Erratum for

Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept.
Nguyen LS, Bretagne M, Arrondeau J, Zahr N, Ederhy S, Abbar B, Pinna B, Allenbach Y, Mira JP, Moslehi J, Rosenzwajg M, Salem JE. Nguyen LS, et al. J Immunother Cancer. 2022 Apr;10(4):e004699. doi: 10.1136/jitc-2022-004699. J Immunother Cancer. 2022. PMID: 35383117 Free PMC article.

Publication types

Actions

LinkOut - more resources

Full Text Sources